FY2025 EPS Estimates for ELDN Reduced by Cantor Fitzgerald

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN) – Cantor Fitzgerald reduced their FY2025 earnings estimates for shares of Eledon Pharmaceuticals in a research report issued to clients and investors on Monday, March 24th. Cantor Fitzgerald analyst P. Stavropoulos now forecasts that the company will earn ($1.23) per share for the year, down from their prior estimate of ($1.12). The consensus estimate for Eledon Pharmaceuticals’ current full-year earnings is ($0.81) per share.

Eledon Pharmaceuticals (NASDAQ:ELDN) last posted its quarterly earnings data on Thursday, March 20th. The company reported ($0.64) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.32). During the same quarter in the prior year, the company earned ($1.00) EPS.

Separately, Guggenheim started coverage on Eledon Pharmaceuticals in a research note on Tuesday, January 28th. They issued a “buy” rating and a $9.00 price objective on the stock.

Eledon Pharmaceuticals Stock Down 3.9 %

ELDN stock opened at $3.47 on Wednesday. The firm has a market cap of $207.79 million, a price-to-earnings ratio of -1.73 and a beta of 0.80. The company’s fifty day simple moving average is $4.15 and its 200 day simple moving average is $3.89. Eledon Pharmaceuticals has a 12-month low of $1.52 and a 12-month high of $5.54.

Institutional Trading of Eledon Pharmaceuticals

Hedge funds have recently modified their holdings of the stock. RA Capital Management L.P. acquired a new stake in Eledon Pharmaceuticals in the fourth quarter worth $14,693,000. First Light Asset Management LLC bought a new position in shares of Eledon Pharmaceuticals during the 4th quarter worth about $9,595,000. Blue Owl Capital Holdings LP acquired a new stake in shares of Eledon Pharmaceuticals in the 4th quarter valued at about $8,075,000. Sphera Funds Management LTD. increased its position in Eledon Pharmaceuticals by 96.7% in the 4th quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company’s stock valued at $10,513,000 after buying an additional 1,254,298 shares in the last quarter. Finally, Frazier Life Sciences Management L.P. acquired a new position in Eledon Pharmaceuticals during the 4th quarter worth approximately $4,848,000. Institutional investors own 56.77% of the company’s stock.

Eledon Pharmaceuticals Company Profile

Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).